Vildagliptin/metformin

Vildagliptin/metformin (trade names Eucreas and Galvumet) is a combination drug for the treatment of type 2 diabetes.[1] It was approved by the European Medicines Agency in 2008.[2] It combines 50 mg vildagliptin with either 500, 850, or 1000 mg metformin.[3]

Vildagliptin/metformin
Combination of
VildagliptinDipeptidyl peptidase-4 inhibitor
MetforminBiguanide antihyperglycemic agent
Clinical data
Trade namesEucreas, Galvumet
Legal status
Legal status
  • In general: ℞ (Prescription only)

References
  1. Halimi, S; Schweizer, A; Minic, B; Foley, J; Dejager, S (2008). "Combination treatment in the management of type 2 diabetes: Focus on vildagliptin and metformin as a single tablet". Vascular Health and Risk Management. 4 (3): 481–492. PMC 2515409.
  2. "EU approves Novartis's Eucreas diabetes drug". Reuters. February 25, 2008.
  3. "Galvumet".
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.